Concurrent disruption of p16(INK4a) and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma

Leukemia

Volumn 14, Issue 10, 2000, Pages 1727-1735

  Gronbaek K ^a,b   De Nully Brown, P ^c   Moller M B ^d   Nedergaard, T ^a   Ralfkiaer, E ^b   Moller P ^b   Zeuthen, J ^a   Guldberg, P ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ARF; Lymphoma; P16; P53; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN MDM2; PROTEIN P16; PROTEIN P19; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CELL CYCLE; CHROMOSOME 9P; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC CODE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REGRESSION ANALYSIS; TUMOR SUPPRESSOR GENE; DNA METHYLATION; GENE DELETION; GENETICS; MUTATION; PATHOLOGY; PROMOTER REGION; SURVIVAL;

ADP-RIBOSYLATION FACTORS; DNA METHYLATION; GENE DELETION; GENES, P16; GENES, P53; HUMANS; LYMPHOMA, NON-HODGKIN; MUTATION; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS;

EID: 0033810808     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401901     Document Type: Article

References (76)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group
2. A predictive model for aggressive non-Hodgkin's lymphoma
3. The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas
4. P53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphoid leukemia
5. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression
6. Deletions and rearrangement of CDKN2 in lymphoid malignancy
7. P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
8. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
9. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
10. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
11. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma
12. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma
13. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis
14. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas
15. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma
16. P16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma
17. P53 mutation is associated with progression in follicular lymphomas
18. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma
19. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas
20. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas
21. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas
22. Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas
23. P53, the cellular gatekeeper for growth and division
24. Cancer cell cycles
25. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
26. P21 is a universal inhibitor of cyclin kinases
27. WAF1, a potential mediator of p53 tumor suppression
28. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
29. Tumor surveillance via the ARF-p53 pathway
30. Signaling to p53: Breaking the MDM2-p53 circuit
31. E1A signaling to p53 involves the p19(ARF) tumor suppressor
32. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
33. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF
34. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
35. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
36. Complex structure and regulation of the p16 (MTS1) locus
37. A novel p16INK4A transcript
38. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies
39. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
40. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
41. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
42. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53
43. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
44. Nucleolar Arf sequesters Mdm2 and activates p53
45. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
46. Selective deletion of exon 1B of the p19(ARF) gene in metastatic melanoma cell lines
47. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
48. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines
49. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
50. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer
51. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer
52. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas
53. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma. A genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb
54. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
55. Germline p16 mutations in familial melanoma
56. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers
57. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B1
58. Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis
59. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues
60. Single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus
61. Use of denaturing gradient gel electrophoresis to study conformational transitions in nucleic acids
62. Single-step DGGE-based mutation scanning of the p53 gene: Application to genetic diagnosis of colorectal cancer
63. Nonparametric estimation from incomplete observations
64. Regression models and life tables
65. Extensive intra- And interindividual heterogeneity of p15(INK4B) methylation in acute myeloid leukemia
66. Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis
67. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
68. The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative β transcript of the p16INK4a/MTS1 gene
69. The human p19ARF protein encoded by the B transcript of the p16INK4a gene is frequently lost in small cell lung cancer
70. Inactivations of p16INK4a-α, p16INK4a-β and p15INK4b genes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced murine lymphomas
71. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence
72. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos
73. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors
74. P14ARF links the tumour suppressors RB and p53
75. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma
76. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies